Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,148,133 papers from all fields of science
Search
Sign In
Create Free Account
apolizumab
Known as:
Monoclonal Antibody Hu1D10
, MOAB Hu1D10
, Monoclonal antibody 1D10
Expand
A humanized monoclonal antibody directed against 1D10, a polymorphic determinant on the HLA-DR beta chain that is expressed on normal and neoplastic…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
10 relations
Broader (2)
Antibodies, Monoclonal, Humanized
Monoclonal Antibodies
Antibody-Dependent Cellular Cytotoxicity
B-Lymphocytes
Complement-Dependent Cytotoxicity
HLA-DR Antigens
Expand
Narrower (2)
Hu1D 10
Remitogen
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Blockade of CD47-Sirpα Interactions Improved Myeloid Effector Cell Mediated Lymphoma Cell Killing By the HLA-DR Antibody Apolizumab
J. Petersen
,
T. Rösner
,
+7 authors
T. Valerius
Blood
2019
Corpus ID: 209239456
Background:Apolizumab (APO) is a humanized IgG1 antibody targeting a HLA-DRβ chain specific epitope, which is expressed by approx…
Expand
2009
2009
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia
T. Lin
,
W. Stock
,
+10 authors
J. Byrd
Leukemia and Lymphoma
2009
Corpus ID: 22328921
Apolizumab (Hu1D10), a humanized monoclonal anti- Human leukocyte antigen -DR β-chain antibody, mediates apoptosis of chronic…
Expand
Review
2008
Review
2008
Newer monoclonal antibodies for hematological malignancies.
J. Castillo
,
E. Winer
,
P. Quesenberry
Experimental Hematology
2008
Corpus ID: 45228506
2008
2008
Caracterização funcional do anticorpo monoclonal humano BH1
Dianne Marie Barroso Catalão
2008
Corpus ID: 191973156
Embora, existam novas terapias e avancos no tratamento do cancro, por vezes, os beneficios esperados nao sao alcancados. O drama…
Expand
2006
2006
A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: A pilot study
J. Rech
,
R. Repp
,
+5 authors
T. Valerius
Leukemia and Lymphoma
2006
Corpus ID: 24080973
Apolizumab is a humanized monoclonal antibody against a polymorphic epitope on HLA DRβ that demonstrated evidence for therapeutic…
Expand
2005
2005
Phase 1 study of combination rituximab with apolizumab in relapsed/refractory B-cell lymphoma and chronic lymphocytic leukemia
K. Dunleavy
,
T. White
,
+7 authors
W. Wilson
2005
Corpus ID: 58435098
6607 Background: Apolizumab (Apo), a humanized IgG1 mAb, targets ID10, and rituximab (R), a chimeric IgG1 mAb, targets CD20, both…
Expand
2005
2005
In Vitro Activity of the Humanized Anti-HLA-DR Antibodies KRN848 and Apolizumab in Non-Hodgkins Lymphoma Cell Lines.
M. Hill
,
G. Weiner
,
B. Link
2005
Corpus ID: 78879405
Apolizumab (Hu1D10) and KRN848 are humanized IgG1 anti-HLA-DR monoclonal antibodies (mAb). Apolizumab binds a polymorphic…
Expand
Review
2003
Review
2003
Monoclonal antibody therapy of chronic lymphocytic leukemia.
B. Mavromatis
,
B. Cheson
Journal of Clinical Oncology
2003
Corpus ID: 37343859
Chemotherapeutic approaches during the last decade have failed to result in major advances in the outcome of patients with…
Expand
2002
2002
Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).
J. Leonard
,
B. Link
Seminars in Oncology
2002
Corpus ID: 21874132
Clinical activity of anti-CD20 monoclonal antibodies both in the unlabeled (rituximab [Rituxan; Genentech, Inc, South San…
Expand
Review
2002
Review
2002
Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).
J. Leonard
,
B. Link
Seminars in Oncology
2002
Corpus ID: 20832729
Clinical activity of anti-CD20 monoclonal antibodies both in the unlabeled (rituximab [Rituxan; Genentech, Inc, South San…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE